Safety and Efficacy of Octreotide LAR Depot in Left Ventricular Assist Device (LVAD) Associate Gastrointestinal (GI)

Trial Profile

Safety and Efficacy of Octreotide LAR Depot in Left Ventricular Assist Device (LVAD) Associate Gastrointestinal (GI)

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Feb 2017

At a glance

  • Drugs Octreotide (Primary)
  • Indications Gastrointestinal haemorrhage
  • Focus Adverse reactions
  • Most Recent Events

    • 28 Apr 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 28 Apr 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top